DFDA

Fluticasone/Salmeterol

Treatment for Chronic Bronchitis

Typical Dosage: 250 mcg/50 mcg twice daily (Diskus) or 230 mcg/21 mcg twice daily (HFA)

Effectiveness
75%
Safety Score
55%
Clinical Trials
5
Participants
40K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
250 mcg/50 mcg twice daily (Diskus) or 230 mcg/21 mcg twice daily (HFA)
Time to Effect
Weeks
Treatment Duration
Lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
10(Treat 10 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$4,000
Monitoring:$600
Side Effect Mgmt:$200
Total Annual:$4,800
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$65,000/QALY
QALYs Gained
0.07
Outcome-Based Costs
Cost per Responder
$6,857
Cost per Remission
$96,000
Comparison vs Salmeterol (LABA monotherapy)
Cost Difference
+$500/year
More expensive
QALY Difference
+0.02 QALYs
Better outcomes
Dominance
No dominance
Fluticasone/Salmeterol Outcomes

for Chronic Bronchitis

Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+70%
Remission Rate
+5%
Common Side Effects
Oral candidiasis
+7.5%
Pneumonia
+4.5%
Hoarseness
+3.5%
Headache
+12.5%
Upper respiratory tract infection
+17.5%

Sources:

nih.gov
atsjournals.org
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
4 completed trials for Fluticasone/Salmeterol in Chronic Bronchitis

Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)

NCT00269126COMPLETEDPHASE3
View Study
150 participants
INTERVENTIONAL
Kyoto, Japan +1 more
Started: Feb 1, 2005

GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)

NCT00269087COMPLETEDPHASE3
View Study
122 participants
INTERVENTIONAL
Kodaira, Japan +4 more
Started: Jan 28, 2005

Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease

NCT00268177COMPLETEDPHASE3
View Study
130 participants
INTERVENTIONAL
Aalborg, Denmark +19 more
Started: Oct 1, 2002

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

NCT00403286COMPLETEDPHASE2
View Study
457 participants
INTERVENTIONAL
Birmingham, United States +48 more
Started: Nov 1, 2006